mirikizumab Archives -

Eli Lilly has the results it was looking for in a second, confirmatory trial of its anti-IL-23p19 antibody

Second trial opens door for Lilly’s mirikizumab in ulcerative colitis

https://pharmaphorum.com/news/second-trial-opens-door-for-lillys-mirikizumab-in-ulcerative-colitis/

Eli Lilly has reported phase 3 results with its ulcerative colitis challenger mirikizumab, as it waits for the

Lilly unveils mirikizumab data in ulcerative colitis as it preps filings

https://pharmaphorum.com/news/lilly-unveils-mirikizumab-data-in-ulcerative-colitis-as-it-preps-filings/

Eli Lilly has walked away from a major indication for its blockbuster hopeful mirikizumab, shelving plans to file

Crowded psoriasis market cuts Lilly’s mirikizumab ambitions

https://pharmaphorum.com/news/crowded-psoriasis-market-cuts-lillys-mirikizumab-ambitions/

A phase 3 trial of Lilly’s inflammatory diseases challenger mirikizumab in ulcerative colitis has met its target –

Lilly’s mirikuzumab hits target in phase 3 ulcerative colitis trial

https://pharmaphorum.com/news/lillys-mirikuzumab-hits-target-in-phase-3-ulcerative-colitis-trial/

Eli Lilly is a latecomer in the new generation of biologic therapies for psoriasis with its mirikizumab candidate,

Lilly’s mirikizumab tops Novartis’ blockbuster Cosentyx in psoriasis

https://pharmaphorum.com/news/lillys-mirikizumab-tops-novartis-blockbuster-cosentyx-in-psoriasis/

mirikizumab